Biocon Biologics Gains Health Canada Approval for Yesintek™ and Yesintek™ IV, Biosimilars to Stelara®

Biocon Ltd
Image Courtesy: Biocon Ltd

Biocon Biologics Ltd (BBL), a global biopharmaceutical company and subsidiary of Biocon Ltd has received Health Canada’s Notice of Compliance (NOC) for Yesintek™ (ustekinumab injection) and Yesintek™ IV (ustekinumab for intravenous infusion)—biosimilar versions of Stelara® and Stelara® IV. The authorization, granted on October 17, clears the way for the Canadian launch of both formulations in mid-October.

Yesintek and Yesintek IV are approved for the treatment of moderate to severe plaque psoriasis in adults and children aged 6–17 years, active psoriatic arthritis in adults, and moderately to severely active Crohn’s disease and ulcerative colitis in adults. These chronic autoimmune conditions affect thousands of Canadians and often require long-term therapy. Health Canada’s decision was supported by an extensive data package confirming that Yesintek is highly similar to Stelara®, with no clinically meaningful differences in efficacy, safety, or immunogenicity.

Both formulations will be offered through the My Biocon Biologics™ patient support program, which assists individuals prescribed with the therapy. Yesintek will be available as subcutaneous injections—45 mg/0.5 mL (prefilled syringe and vial) and 90 mg/mL (prefilled syringe)—while Yesintek IV will be offered as an intravenous infusion (130 mg/26 mL, 5 mg/mL).

Shreehas Tambe, CEO and Managing Director of Biocon Biologics, said the approval represents a key milestone in expanding patient access to advanced biologic therapies. “Health Canada’s authorization of Yesintek marks another important step in our mission to make high-quality biosimilars accessible to patients globally,” he said. “Following our successful U.S. introduction, this approval broadens our North American footprint and offers Canadian patients a more affordable option for managing autoimmune diseases.”

Ramy Ayad, Head of Canada for Biocon Biologics, added, “We’re proud to bring Yesintek to Canadian patients as a trusted ustekinumab biosimilar. Our goal is to drive biosimilar adoption, improve health outcomes, and generate meaningful savings for Canada’s healthcare system. By expanding access in both public and private markets, we aim to help strengthen a sustainable biosimilars ecosystem that benefits all Canadians.”

Biocon Biologics is a fully integrated global biosimilars company, leveraging its “lab-to-market” expertise to serve over six million patients across more than 120 countries. With 10 commercialized biosimilars addressing critical diseases in areas such as immunology, oncology, diabetology, and ophthalmology, the company continues to expand its portfolio, which currently includes 20 biosimilar assets in development. Its commitment to innovation, affordability, and sustainability has earned it recognition in the S&P Global Sustainability Yearbook 2025 for its progress on environmental, social, and governance (ESG) goals.